bioRxiv Science⌕ Search

Biology subjects

Bussema, L.

Publications and source records attributed to Bussema, L..

2 recordsLinked to original sources

Helix: a structure-aware deep learning model for accurate prediction of A-to-I RNA editing by endogenous ADARs

Adenosine deaminase acting on RNA (ADAR) converts adenosine to inosine within double-stranded RNA (dsRNA) and can be co-opted for therapeutic RNA editing by introducing dsRNA substrates in trans using programmable guide RNAs (gRNAs). However, ADARs natural promiscuity necessitates sophisticated gRNA designs to achieve efficient and specific editing. Here we present Helix, a predictive model that achieves highly accurate, zero-shot per-adenosine editing predictions for any target sequence. Helixs performance arises from two architectural choices: a transformer framework that scales effectively with increasing and imbalanced training data; and a structure-aware attention mechanism that incorporates predicted RNA secondary structure, a key determinant of ADAR activity. Helixs predictive accuracy enables seamless integration with DeepREAD, our previously reported generative model, in a noisy-student distillation framework termed DeepHelix. This workflow supports both zero-shot gRNA design and the generation of complex, constraint-based designs. We demonstrate DeepHelixs utility by designing gRNAs that efficiently edit a therapeutically relevant adenosine and by leveraging its flexible design space to engineer species cross-reactive gRNAs to accelerate pre-clinical development.

bioengineering↗

DrugMap: A quantitative pan-cancer analysis of cysteine ligandability

Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed DrugMap, an atlas of cysteine ligandability compiled across 416 cancer cell lines. We unexpectedly find that cysteine ligandability varies across cancer cell lines, and we attribute this to differences in cellular redox states, protein conformational changes, and genetic mutations. Leveraging these findings, we identify actionable cysteines in NF{kappa}B1 and SOX10 and develop corresponding covalent ligands that block the activity of these transcription factors. We demonstrate that the NF{kappa}B1 probe blocks DNA binding, whereas the SOX10 ligand increases SOX10-SOX10 interactions and disrupts melanoma transcriptional signaling. Our findings reveal heterogeneity in cysteine ligandability across cancers, pinpoint cell-intrinsic features driving cysteine targeting, and illustrate the use of covalent probes to disrupt oncogenic transcription factor activity.

systems biology↗